aid: instylla
name: Instylla
description: >-
  Instylla, Inc. is a privately held medical device company headquartered in Bedford, Massachusetts,
  founded in 2017 by Incept LLC to develop next-generation resorbable liquid embolic agents for
  interventional radiology, with initial clinical applications in interventional oncology and
  peripheral hemostasis. Its flagship product, the Embrace Hydrogel Embolic System, received U.S.
  FDA premarket approval (PMA) in August 2025 for the embolization of hypervascular tumors in
  peripheral arteries of 5 mm or less, and began commercial use in January 2026; the company also
  markets the FDA-cleared Tembo Embolic System. Embrace is delivered as two injectable
  polyethylene-glycol precursors that crosslink in the vessel lumen into a soft hydrogel and then
  resorb by hydrolysis over roughly eleven months. Instylla is a device manufacturer rather than a
  software vendor: it publishes no developer program, no public API, and no machine-readable
  interface contract.
image: https://instylla.com/wp-content/uploads/2021/08/Instyla-Social-Share-Image-v2.jpg
url: https://raw.githubusercontent.com/api-evangelist/instylla/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-08-23'
modified: '2026-08-23'
tags:
- Company
- Medical Devices
- Healthcare
- Interventional Radiology
- Oncology
- Embolization
- Life Sciences
- Biomaterials
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/instylla-domain-security.yml
- type: Website
  url: https://instylla.com/
- type: About
  url: https://instylla.com/about/
- type: Blog
  url: https://instylla.com/press-releases/
- type: BlogRSS
  url: https://instylla.com/feed/
- type: ContactUs
  url: https://instylla.com/contact/
- type: Careers
  url: https://instylla.com/careers/
- type: CaseStudies
  url: https://instylla.com/case-studies/
- type: LinkedIn
  url: https://www.linkedin.com/company/instylla/
- type: Twitter
  url: https://twitter.com/instylla
- type: SecondaryMarketListing
  url: https://forgeglobal.com/instylla_stock/
x-enrichment:
  date: '2026-08-23'
  status: minimal
  artifacts_added: 3
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: >-
    Instylla is an FDA-PMA medical device manufacturer whose product is an injectable hydrogel
    embolic agent, not software; its entire web presence is a seven-page WordPress marketing site
    (Solutions / Clinical Study / Case Studies / About / News / Careers / Contact) whose only
    login is a clinical "Study Portal" for trial sites, and the full Wayback URL inventory for
    instylla.com contains no developer, docs or API path ever.
  evidence:
  - url: https://instylla.com/openapi.json
    status: 202
  - url: https://instylla.com/.well-known/agent-card.json
    status: 202
  - url: https://api.github.com/search/repositories?q=instylla
    status: 200
  - url: https://pypi.org/pypi/instylla/json
    status: 404
  checked: '2026-08-23'